[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554729":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":24,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":24,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":24,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Artialis","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Inflammatory bowel disease cohort","OTHER","60 patients diagnosed with colonic inflammatory bowel disease",[13],"Procedure: biological samples collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Control cohort","60 control patients without inflammatory bowel diseases",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","biological samples collection","Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies",[15,9],null,[26],{"name":27,"affiliation":28,"role":29},"Catherine Van Kemseke, MD","Centre Hospitalier Universitaire de Liege","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Bérénice Costes","CONTACT","042670888","berenice.costes@artialis.com",[37],{"facility":38,"status":39,"city":40,"state":24,"zip":24,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"CHU de Liège","RECRUITING","Liège","Belgium","BE",{"type":44,"coordinates":45},"Point",[46,47],5.56749,50.63373,{"lat":47,"lon":46},[50,53],{"name":51,"role":33,"phone":24,"phoneExt":24,"email":52},"Claire Mesnil","claire.mesnil@artialis.com",{"name":27,"role":29,"phone":24,"phoneExt":24,"email":24},{"type":55,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100554729","setting-up-a-cohort-of-patients-with-inflammatory-bowel-disease-and-a-cohort-of-patients-without-chronic-inflammatory-bowel-disease-100554729",false,"NCT06502873","Setting up a Cohort of Patients With Inflammatory Bowel Disease and a Cohort of Patients Without Chronic Inflammatory Bowel Disease","Setting up a Cohort of Patients With Inflammatory Bowel Disease and a Cohort of Patients Without Chronic Inflammatory Bowel Disease in the Context of the Translational Study of Biomarkers of Intestinal Dysbiosis (ELITE Walloon Project)","ELITE","Inclusion Criteria:\n\nGeneral criteria:\n\n* Male or female ≥ 18 years old\n* Able to follow the instructions of the study\n* Having signed an informed consent\n\nSpecific for Crohn cohort:\n\n* A confirmed diagnosis of IBD\n* Rectal or colonic or ileocolic involvement\n* Patients with CD presenting inflammatory flare and disease extent in the colon or ileocolic region with:\n* A clinical activity defined by an average of four or more instances of very soft or liquid stools daily or an abdominal pain score of 2 or more OR a CDAI (CD Activity Index) ≥ 220 OR a Harvey-Bradshaw Index \\> 8 OR a faecal calprotectin ≥ 250 µg\u002Fg And\n* A endoscopic activity defined by a SES-CD (Simple Endoscopic Score for Crohn Disease) ≥ 6 or a CDEIS (CD Endoscopic Index score) ≥ 7\n* Patients with UC presenting inflammatory flare with:\n\nA clinical activity defined by a modified Mayo score ≥ 3 OR a Simple Clinical Colitis Activity Index ≥5 OR Patient Reported Outcome (PRO2) ≥ 4 with a subscore of rectal bleeding ≥1 OR a faecal calprotectin ≥ 250 µg\u002Fg AND An endoscopic activity defined by a Mayo endoscopic sub-score ≥ 2\n\nSpecific for Control cohort:\n\nPatient with no colonic lesion(s) visible during the endoscopical examination (neither Crohn's nor other colitis nor cancer)\n\nExclusion Criteria:\n\nGeneral criteria:\n\n* Commercial Pharmaceutical probiotic administration within the previous month\n* Treatment with antibiotics (whatever the route of administration) within last 3 months\n* Non-remission Cancer or in remission for less than 6 months\n* Any contraindication to colonoscopy and\u002For biopsy, left to PI discretion\n* Under guardianship or judiciable protection\n* Pregnant or breastfeeding women\n* Currently participating or having participated in the last 3 months to a clinical study with investigational medicine or food supplement\n\nSpecific for Crohn cohort:\n\n* Crohn disease localized only in Ileum\n* Inflammatory colon pathology other than Crohn's (infectious, drug-induced,…)","ALL","18 Years",{"count":67,"type":68},120,"ESTIMATED","INTERVENTIONAL",[71],"NA","The objective of this study is to constitute cohorts of IBD versus non-IBD patients to identify (a) new biomarker(s) of intestinal dysbiosis associated with inflammatory bowel disease, and develop a prototype for assaying such marker(s) in blood.",[74],"Inflammatory Bowel Disease (IBD)",[76,77,78],"cohort","BEV","intestinal dysbiosis","2026-01-27",{"date":81,"type":82},"2026-01-28","ACTUAL",{"date":84,"type":82},"2024-06-28",{"date":86,"type":68},"2026-12-31",{"name":5,"class":6},1]